1[1]Gandara DR, Lara PN Jr, Goldberg Z, et al. Neoadjuvant therapy for non-small cell lung cancer. Anticancer drugs,2001,12(Suppl 1)∶ S5-9.
2[2]Armand JP. Docetaxel (Taxotere) in the treatment of non-small cell lung cancer (NSCLC) --is there a role for a new chemotherapy programme? Gan To Kagakv Ryoho,2000,27(Suppl 2)∶223-230.
3[3]Robinet G, Thomas P, Perol M, et al. Phase Ⅱ study of docetaxel in inoperable advanced non small cell lung cancer. Bull Cancer,2000,87(3)∶253-258.
4[4]Fossella FV. Overview of docetaxel (Taxotere) in the treatment of non-small cell lung cancer. Semin Oncol,1999,26(3 Suppl 11)∶4-8.
5[5]Le Chevalier T, Berille J, Zalcberg JR, et al. Overview of docetaxl (Taxotere) /cisplatin combination in non-small cell lung cancer. Semin Oncol,1999,26(3 Suppl 11)∶13-18.
7[7]Green MR. The current status of docetaxel for advanced non-small cell lung cancer. Anticancer Drugs,2001,12(Suppl 1)∶S11-16.
8[8]Spiridonidis CH, Lanfman LR, Carman L, et al. Second-line che-motherapy for non-small-cell lung cancer with docetaxel and weekly gemcitabine: a phase Ⅱ trial. Ann Oncol,2001,12(1)∶89-94.
